The U.S. Trade Representative launched a Section 301 investigation into Germany’s pharmaceutical pricing policies on June 18, 2026, citing evidence that U.S. consumers pay 3.9 times more than Germans for brand-name drugs. The probe examines how Germany’s reference pricing and reimbursement systems shift global R&D costs onto American patients. Public comments are due August 21, 2026, with a hearing scheduled for September 12, 2026. Germany accounts for 11% of global pharma sales but contributes under 5% of industry R&D investment. The investigation falls under the Trade Act of 1974 and could lead to tariffs or procurement restrictions.
The U.S. Trade Representative has launched a Section 301 trade investigation targeting Germany to determine whether the country uses unfair pricing policies and practices to underpay for pharmaceuticals at the expense of U.S. consumers, according to a Federal Register notice.
Scope and timeline of the investigation
The trade office investigation, launched on June 18, 2026, will review if Germany’s actions result in the U.S. paying a disproportionate share of global research and development costs for innovative pharmaceuticals. The probe is formally titled “Investigation into Germany’s Pharmaceutical Pricing Policies and Practices” and is being conducted under Section 301 of the Trade Act of 1974.
The U.S. Trade Representative (USTR) stated that the investigation will examine specific mechanisms including Germany’s reference pricing system, price negotiations with manufacturers, and reimbursement frameworks used by statutory health insurance funds. These policies, notice, may depress prices paid by German consumers relative to those in the United States — thereby shifting R&D cost burdens onto American patients and payers.
Price disparity and cost-shifting claims
“U.S. consumers pay approximately 3.9 times as much as the prices consumers in Germany pay for brand-name drugs,” the notice says. As a result, “higher U.S. prices support and fund global R&D costs for innovative pharmaceutical manufacturers and, thereby, unfairly shift Germany’s fair share of costs for pharmaceutical innovation to U.S. consumers.”
This quantitative comparison forms the central factual basis of the USTR’s case. The notice cites data from the Organisation for Economic Co-operation and Development (OECD) and the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Planning and Evaluation, both of which confirm substantial cross-national price differentials for identical branded therapeutics.
The USTR further notes that Germany accounts for roughly 11% of global pharmaceutical sales but contributes less than 5% of total industry R&D investment — a gap the agency attributes to systematic underpricing rather than differences in therapeutic focus or market size.
Stakeholder consultation and next steps
A public comment period opened on June 22, 2026, with written submissions due by August 21, 2026. The USTR will hold a public hearing on September 12, 2026 in Washington, D.C., where representatives from U.S. pharmaceutical companies, health insurers, patient advocacy groups, and German industry associations are expected to testify.
Antone Gonsalves, Reporter at Supply Chain Dive, reported on the announcement. The investigation follows similar Section 301 probes previously initiated against France (2021, digital services tax) and India (2023, solar cell import restrictions), both of which resulted in negotiated settlements.
If the USTR finds Germany’s practices violate U.S. trade rights, it may recommend remedies including tariffs on German pharmaceutical exports, exclusion from U.S. government procurement programs, or suspension of bilateral cooperation agreements related to health technology innovation.
Source: Supply Chain Dive
Compiled from international media by the SCI.AI editorial team.
